Hints and tips:
...Top Pharma picks are ROG SW, NOVOB DC and AZN LN....
...Torrent Pharma also withdrew. “This is a business that has gone sideways and the buyers must believe in turning the business around,” said a person with direct knowledge of the auction....
...Carlyle wins fight for Akzo Nobel speciality chemicals arm A group of investors led by US buyout giant Carlyle agreed to pay €10.1bn including debt for Akzo Nobel’s specialty chemicals unit after months...
...Teva could use a similar shot in the arm, after deciding to spend nearly $40bn in cash and shares on Actavis, another generic pharma specialist, in 2015....
...(NYT) A pharma M&A boom could boost innovation: With a wave of pharma mergers potentially on the horizon, companies may be set to unleash a new age of innovation....
...Oncology drugs, particularly new treatments that take advantages of innovations in genomics to make targeted therapies, are seen as critical elements to larger pharma companies’ portfolios, making specialty...
...specialty groups such as Ariad enticing takeover candidates....
...“The key M&A trends in 2014 and 2015 were specialty pharma companies acquiring revenue and cutting costs using cheap debt. That has disappeared....
...Teva, the largest generic drugmaker in the world, set the stage for the biggest pharma deal of 2015 by launching an unsolicited $40bn offer to buy its nearest rival Mylan....
...per cent last year, according to Express Scripts, the largest pharmacy-benefits manager, compared with a 5.6 per cent jump in overall US healthcare costs, partly because a new generation of expensive “specialty...
...Both pharmacy benefits managers and pharmacy retailers have been active in striking deals in recent years, in an effort to exert pressure on generic and specialty pharma drugmakers....
...Most recently Mylan, the US-based generic maker, was given the regulatory go ahead for the $1.6bn acquisition of Agila Specialties, the Indian vaccine and injectables producer....
...“Meda regularly appears as a buyout candidate in a global Specialty Pharma sector that is subject to ongoing consolidation,” said analysts at Swedbank in a note....
...Related reading: Emerging market pharma spending to nearly double by 2016, beyondbrics Corporate watch: Adcock Ingram looks to India as well as Africa, beyondbrics Aspen Pharmacare extends EM reach, beyondbrics...
...“This,” said Adrian Whitfield, the group’s chief executive, “marks the final step in a long process of transforming Yule Catto into a substantial highly focused specialty polymer business.”...
...In the small-cap arena, counterbid rumours supported NeuTec Pharma, up 0.5 per cent to ?10.71. NeuTec recently recommended a ?10.50-a-share bid from Novartis....
International Edition